Previous 10 | Next 10 |
home / stock / rhhbf / rhhbf news
2023-11-19 12:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Perfectly Priced Healthcare Giant Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event (Transcript) Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise ...
2023-11-19 09:56:29 ET Summary WisdomTree International Quality Dividend Growth Fund selects ex-North America dividend stocks with quality and expected earnings growth characteristics. The fund is well-diversified across countries, sectors, and holdings, with a focus on Europe. ...
2023-11-16 12:35:07 ET Summary Recursion Pharmaceuticals, Inc. proof-of-concept data, from the phase 2 SYCAMORE study using REC-994 for the treatment of patients with Cerebral Cavernous Malformation, expected in the 2nd half of 2024. Safety and preliminary efficacy data, from the ...
2023-11-09 06:54:33 ET More on AstraZeneca AstraZeneca: Revenue Softening Possible, Profits To Rise AstraZeneca: Buy This Blue-Chip Bargain For A Richer Retirement AstraZeneca: Hidden Gem Of The Pharma Sector Is A Great Buy Opportunity AstraZeneca lifts forec...
2023-11-07 17:07:59 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-11-06 19:43:49 ET Summary Repare Therapeutics presented preliminary results from the phase 1 MYTHIC study using the lunresertib and camonsertib combination for the treatment of patients with multiple solid tumor types. The biotech plans to complete the phase 1 expansion porti...
2023-11-03 08:40:40 ET More on Regeneron Regeneron Pharmaceuticals, Inc. (REGN) Q3 2023 Earnings Call Transcript Regeneron Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare ...
2023-10-31 09:14:03 ET More on Sarepta Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy Sarepta: Broad Label Expansion Possible With Q4 2023 Catalyst Sarepta Eyes Broadened La...
2023-10-31 08:56:11 ET Summary Monte Rosa Therapeutics is making progress in developing molecular glue degraders to target undruggable diseases. The company has released preliminary PK/PD data for its MGD MRT-2359, showing promising results in MYC-driven solid tumors. Monte Ro...
2023-10-29 12:00:27 ET More on PBMs Cigna PBM unit Express Scripts sued for overcharging pharmacies FTC investigating purchasing organizations that work on behalf of PBMs Eli Lilly, Novo, Sanofi and leading PBMs accused in California over insulin prices CVS H...
News, Short Squeeze, Breakout and More Instantly...
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare Canada NewsWire The report shows digital health technologies demonstrate value, yet integrating th...
Development in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions Canada NewsWire Roche's Cerebrospinal Fluid (CSF) assays address unmet needs in the detection of amyloid pathology by offering greater accessibility and support...